Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.58 |
| ▸ | MIF | P14174 | 11/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | GLA | P06280 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15842332 | 0.81 | PGR (0.43) | HSD17B3MEN1KMT2AKDM4EGAA | |
| SCHEMBL18535489 | 0.81 | MIF (0.65) | MIFMEN1KMT2AKDM4EGLA | |
| SCHEMBL28642209 | 0.80 | MAOB (0.47) | HSD17B3MIFMEN1KMT2AALDH1A1 | |
| SCHEMBL12040002 | 0.80 | CA12 (0.53) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL526705 | 0.80 | GAA (0.58) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL15842386 | 0.78 | HTT (0.39) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL25848460 | 0.78 | MIF (0.62) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL21761390 | 0.78 | MIF (0.62) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL10794401 | 0.77 | HSD17B3 (0.64) | HSD17B3MIFMEN1KMT2AKDM4E | |
| SCHEMBL7544470 | 0.77 | HPGD (0.55) | KDM4EGLAGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091022-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | SHIONOGI & CO., LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12521375-B2 | Pharmaceutical composition for treating fatty liver disease | SHIONOGI & CO., LTD. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250257072-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-4590676-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-119907800-A | Hexahydro-2H-pyrido [2,1-a ] isoquinoline VMAT2 inhibitors and methods of use thereof | 纽罗克里生物科学有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-113717198-B | Process for preparing substituted polycyclic pyridone derivatives and crystals thereof | 盐野义制药株式会社 | 2025-03-07 | — | — | CN | disclosed |
| US-20250041279-A1 | THERAPEUTIC MEDICINE FOR HEART DISEASE OR SKELETAL MUSCLE DISEASE | SHIONOGI & CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| CN-112313238-B | Tetrahydropyranoxazine derivatives with selective BACE1 inhibiting activity | 盐野义制药株式会社 | 2025-01-17 | — | — | CN | disclosed |
| EP-3741760-B1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2024-12-04 | — | — | EP | disclosed |
| EP-4458348-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20030186349-A1 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation | 2003-10-02 | — | — | US | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1140888-B1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | VERTEX PHARMA SAN DIEGO LLC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030027238-A1 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation | 2003-02-06 | — | — | US | disclosed |
| US-6514687-B1 | Screening a candidate compound for activity as a Cytochrome P450 enzyme substrate by contacting the compound, enzyme, and a reagent chromogen comprising the ether of a phenolic dye such as a coumarin, resofurin or fluorescein dye | VERTEX PHARMACEUTICALS (SAN DIEGO), LLC | 2003-02-04 | — | — | US | disclosed |
| US-6420130-B1 | CHEMICAL COMPOUND FOR USE IN THE DETECTION OF PREFERENTIAL ENZYMATIC POLYPEPTIDE | AURORA BIOSCIENCES CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-1140888-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | Aurora Biosciences Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6143492-A | COMPOUND USEFUL AS AN OPTICAL PROBE; DRUG SCREENING | AURORA BIOSCIENCES CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000035900-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | AURORA BIOSCIENCES CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257072-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | C3AR1, CYP4B1, ADORA2B | HSD17B3 793/4885MIF 4062/4885MEN1 2719/4885 |
| US-20250041279-A1 | THERAPEUTIC MEDICINE FOR HEART DISEASE OR SKELETAL MUSCLE DISEASE | TNNT2, CPT1B, TNNC1 | HSD17B3 1019/4885MIF 4868/4885MEN1 4759/4885 |
| US-20260091022-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | SLC10A1, GLP1R, SLC10A2 | HSD17B3 168/4885MIF 3750/4885MEN1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.